Crossbow Therapeutics Launches With $80 Million In Series A Financing To Advance A Novel Class Of Antibody Therapies That Mimic T-Cell Receptors To Treat Cancer

Jul 11, 2023•over 2 years ago

Amount Raised

$80 Million

Round Type

series a

CambridgeBiotechnologyHealth Care

Description

Crossbow Therapeutics, Inc., a biotechnology company developing a novel class of potent and precise antibody therapies to treat a broad range of cancers, today announced an $80 million Series A funding round led by MPM BioImpact and Pfizer Ventures, with participation from Polaris Partners, BVF Partners, Eli Lilly and Company, Mirae Asset Venture Investment, and Mirae Asset Capital.

Company Information

Company

Crossbow Therapeutics

Location

Cambridge, Massachusetts, United States

About

Crossbow Therapeutics, Inc., is a biotechnology company determined to improve the lives of people with cancer by unlocking the therapeutic potential of T-cell receptor (TCR)-mimetic antibodies. The company’s T-Bolt™ therapies are next-generation, easily assembled immunotherapies directed with high precision at previously unreachable cancer cell targets. Crossbow’s efficient and selective approach is designed to target the entire universe of cancer proteins, dramatically expanding the potential of antibody therapy to address many types of cancer.

Related People

3 contacts

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Crossbow Therapeutics Launches With $80 Million In Series A Financing To Advance A Novel Class Of Antibody Therapies That Mimic T-Cell Receptors To Treat Cancer

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Funding Insights

Company Information